Skip to main content

Table 2 Infused ADV-VST characteristics

From: Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial

Patient ADV-VST origin Donor ADV response (SFCs per 106 PBMC) VST dose (×103 viables CD3+ IFNγ+/kg) VST dose (×103 CD4+ IFNγ+/kg) [enrichment (% of CD4)] VST dose (×103 CD8+ IFNγ+/kg) [enrichment (% of CD8)]
01-01 HSC donor 96 0.39 0.35 [68.4] 0.04 [7.1]
07-03 HSC donor 527 28.10 26.0 [78.5] 2.10 [15.8]
09-04 HSC donor 177 0.25 0.12 [51.0] 0.13 [45.9]
06-05 HSC donor UN 0.92 0.34 [47.6] 0.58 [56.6]
07-06 Haplo donor (mother) UN 1.21 0.66 [15.1] 0.55 [11.7]
02-08 Haplo donor (mother) 364 1.10 0.60 [87.7] 0.50 [76.4]
11-10 Haplo donor (sister) 446 3.90 2.99 [96.0] 0.90 [93.5]
12-11 Haplo donor (mother) 370 9.14 8.13 [94.3] 1.01 [90.6]
08-12 Haplo donor (mother) 561 8.28 7.31 [84.5] 0.98 [69.6]
01-13 HSC donor 271 1.41 1.34 [81.9] 0.08 [39.8]
12-14 Haplo donor (mother) 492 9.38 7.70 [96.1] 1.61 [88.2]
Mean   367 5.83 5.05 [72.8] 0.77 [54.1]
SD   160 8.23 7.66 [25.5] 0.65 [32.5]
  1. ADV-VST adenovirus-specific T cells, SFC secretion-forming cells, PBMC peripheral blood mononuclear cells, Haplo donor haploidentical donor, SD standard deviation, UN unavailable